ArticleJournal of translational medicine2026
MiPEP133 enhances anti-tumor immunity in nasopharyngeal carcinoma by activating CD8 + T cells.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundActivation of the tumor immune microenvironment (TIME) is crucial for controlling nasopharyngeal carcinoma (NPC) progression. This study aims to identify miPEP133 as novel therapeutic targets for NPC treatment.
methodsRNA-Seq was used to assess miPEP133's effect on NPC cells and T-cell-related signaling pathways. IHC measured miPEP133 protein expression in human NPC tissues. Functional assays evaluated miPEP133's role in anti-tumor immunity. NPC cells were co-cultured with T cells to examine miPEP133's impact on CD8 + T-cell activation, cytotoxic factor secretion, and DC maturation via flow cytometry, ELISA, and a subcutaneous xenograft model. Immunofluorescence (IF), ELISA, and Western blot assessed miPEP133's effect on NPC cell immunogenicity. Finally, electron microscopy, IF, Western blot, and RT-qPCR systematically verified miPEP133's molecular mechanism in NPC cells and its immunomodulatory effects on T cells.
resultsThis study confirmed that miPEP133 expression in NPC was positively correlated with CD8 + T-cell-mediated anti-tumor immunity and may serve as an independent prognostic factor for survival. High miPEP133 increased CD8 + T-cell infiltration, enhanced secretion of Granzyme B, IFN-γ, and IL-2 from CD8 + T cells, and promoted DC maturation. Moreover, miPEP133 boosted tumor cell antigen presentation via endoplasmic reticulum stress. In a nude mouse xenograft model, miPEP133 significantly inhibited tumor growth, further validating its role in enhancing anti-tumor immunity. Mechanistically, miPEP133 activated type I interferon responses by regulating the STING pathway, subsequently reactivating T-cell immunity via the JAK1/STAT1/STAT4 axis.
conclusionsMiPEP133 overexpression in NPC cells significantly enhances CD8 + T-cell-mediated immunity, revealing a novel anti-tumor mechanism. These findings demonstrate miPEP133's critical role in shaping the NPC immune microenvironment, highlighting its therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.